DEFC14A: Standard BioTools Aims for Growth After SomaLogic Merger, Faces Board Challenge

Standard BioTools highlights 2023 achievements, including revenue growth and cost reductions, while facing a proxy fight from Madryn Health Partners at the upcoming annual meeting.

Summary

• Standard BioTools is soliciting proxies for its 2024 annual meeting, where stockholders will vote on director elections, executive compensation, auditor ratification, an equity incentive plan amendment, and a stockholder proposal to declassify the board.
• In 2023, Standard BioTools achieved 9% revenue growth to $106 million, with instrument revenue up over 40%.
• The company also reduced operating expenses by $26 million (17%) and improved net cash used for operating activities by over $46 million (52%).
• The merger with SomaLogic resulted in pro forma revenue of $192 million in 2023.
• Madryn Health Partners intends to nominate two directors in opposition to the Board's nominees and propose a non-binding resolution to declassify the Board.
• The Board recommends voting FOR its director nominees, executive compensation, auditor ratification, and the equity incentive plan amendment, and AGAINST the Madryn proposal.
• The company is seeking stockholder approval to amend its 2011 Equity Incentive Plan to increase the number of shares available for issuance by 19,125,000 shares.
• The Board believes the classified board structure promotes stability and protects against abusive takeover tactics.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. There are positive aspects such as revenue growth and cost reductions, but the proxy fight and potential risks temper the overall outlook.

Positives

• Standard BioTools achieved revenue growth and significant cost reductions in 2023.
• The SomaLogic merger has expanded the company's technology portfolio and market reach.
• The Board is committed to good corporate governance and stockholder engagement.
• The company has eliminated the Series B Preferred Stock capital structure and governance rights.

Negatives

• The company is facing a proxy fight from Madryn Health Partners.
• Madryn believes that the terms of the Merger undervalued SomaLogic.
• The company is incurring significant costs related to the proxy solicitation, estimated at $750,000.

Risks

• The outcome of the proxy contest with Madryn Health Partners is uncertain.
• The company's future performance is subject to numerous risks and uncertainties, including those related to the SomaLogic merger, restructuring activities, and market conditions.
• The company's ability to attract and retain key personnel may be impaired if the equity incentive plan amendment is not approved.

Future Outlook

The company anticipates a year of execution against operational and financial goals in 2024 and continues to identify potential strategic acquisitions.

Management Comments

• 'Standard BioTools performance in 2023 demonstrated that our strategic transformation and focus on operational excellence is taking hold.'
• 'We have validated our belief that the model of being together is the only proven business model to-date in our space, and the recent merger with SomaLogic has fully activated this plan.'

Industry Context

The company aims to be a diversified leader in life sciences tools, serving the proteomics customer end market in the beyond-genomics era. They are actively seeking strategic acquisitions to diversify revenues and empower customers with differentiated technologies.

Comparison to Industry Standards

• The company's burn rate is expected to be between the 50th and 75th percentiles of its compensation peer group.
• The company's overhang is expected to be between the 50th and 75th percentiles of its compensation peer group.
• Comparible companies are SOPHiA GENETICS SA (Nasdaq: SOPH), Exact Sciences (Nasdaq: EXAS), and 23andMe (Nasdaq: ME).

Stakeholder Impact

• The outcome of the proxy contest could impact the composition of the Board and the company's strategic direction.
• The equity incentive plan amendment is intended to attract and retain key personnel, benefiting employees and stockholders.
• The company's performance and strategic decisions will impact customers, suppliers, and other stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting on June 27, 2024.
• The Board will consider the outcome of the stockholder vote on the declassification proposal.

Key Dates

Keywords

Standard BioTools, SomaLogic, proxy statement, annual meeting, director election, executive compensation, equity incentive plan, Madryn Health Partners, board declassification, revenue growth, cost reduction, merger, corporate governance